References 1. Curado MP, Edwards B, Shin HR, et al. Cancer Incidence in Five Continents, vol. IX. Lyon: International Agency for Research on Cancer, 2007. 2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2012, National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2012/, accessed April 2015. 3. Ferlay J1, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. 4. Redaniel MTM, Laudico AV, Lumague MRM, Mapua CA, Patama T, Pukkala E. Cancer in the Philippines, Vol IV Part 1 Cancer Incidence 1998-2002. Manila: Philippine Cancer Society, 2008. 5. Grodski S, Brown T, Sidhu S, et al. Increasing incidence of thyroid cancer is due to increased pathologic detection. Surgery. 2008;144(6):1038-43. 6. Mendoza A, Shaffer B, Karakla D, Mason ME, Elkins D, Goffman TE. Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. Thyroid. 2004;14(2):133-40. 7. Biondi B, Fazio S, Carella C, et al. Control of adrenergic overactivity by betablockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1994;78(5):1028-33. 8. Almeida, JP, Vartanian, JG, Kowalski, LP. Clinical predictors of quality of life in patients with initial differentiated thyroid cancers. Arch Otolaryngol Head Neck Surg. 2009;135(4):342-6. 9. Rubic M, Kuna SK, Tesic V, Samardzic T, Despot M, Huic D. The most common factors influencing on quality of life of thyroid cancer patients after thyroid hormone withdrawal. Psychiatr Danub. 2014;26 Suppl 3:520-7. 10. Gómez M, Gutiérrez R, Castellanos S, Vergara M, Pradilla Y. Psychological well-being and quality of life in patients treated for thyroid cancer after surgery. Terapia Psicologica. 2010:28(1):69-84. 11. Centers for Disease Control and Prevention. Measuring healthy days: Population assessment of health-related quality of life. Atlanta, Georgia: Centers for Disease Control and Prevention, 2000. 12. Husson O, Haak HR, Oranje WA, Mols F, Reemst PH, van de Poll-Franse LV. Health-related quality of life among thyroid cancer survivors: A systematic review. Clin Endocrinol (Oxf). 2011;75:544–54. 13. Tan LG, Nan L, Thumboo J, Sundram F, Tan L. Health-related quality of life in thyroid cancer survivors. Laryngoscope. 2007;117(3):507-10. 14. Lee JI, Kim SH, Tan AH, et al. Decreased health-related quality of life in disease-free survivors of differentiated thyroid cancer in Korea. Health Qual Life Outcomes. 2010;15;8:101. 15. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365– 76. 16. Husson O, Haak HR, Mols F, et al. Development of a disease-specific healthrelated quality of life questionnaire (THYCA-QoL) for thyroid cancer survivors. Acta Oncol. 2013;52(2):447-54 17. Johnson, C, Aaronson N, Blazeby JM, et al. EORTC Quality of Life Group Guidelines for Developing Questionnaire Modules, 4th Edition. April 2011. 18. Nunnally JC, Bernstein IH. Psychometric theory. New York: McGraw-Hill, 1994. 19. Jeong Y, Choi J, Ahn A, et al. Validation of the Korean version of the thyroid cancer-specific quality of life questionnaire. Ann Surg Treat Res. 2015;89(6): 287–294. 20. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997;7:613–9. 21. EORTC QOL Module for Thyroid Cancer (QLQ-THY). http://groups.eortc.be/qol/eortc-qol-module-thyroid-cancer-qlq-thy.